C04835: Novel Peptide Inhibitors of AngiogenesisNovelty:
Identification of 156 novel peptide fragments with putative anti-angiogenic properties.
Value Proposition:
Anti-angiogenic inhibitors are proving to be a very effective way of targeting a variety of cancers with metastatic potential. This invention features an empirical list of several families of peptides with putative anti-angiogenesis properties which were identified based on the homology and localization of anti-angiogenic peptide sequences identified in well-studied candidates such as angiostatin, endostatin etc. Other advantages include:.
• Ability to inhibit adhesion and induction of apoptosis, two key components of angiogenesis.
• Posses anti-angiogenic properties such as inhibition of migration and tube formation.
• Potential to be developed as a therapeutic treatment option for a variety of angiogenic cancers.
Technical Details:
Johns Hopkins researchers have identified 156 novel peptides with putative anti-angiogenic properties. These novel peptides are modulators of angiogenesis and were identified using a systematic computational methodology based on bioinformatics. The peptides belong to the protein families of thrombospondins, collagen type IV, CXC Chemokines, Kringle containing proteins, somatotropins and tissue inhibitors of metalloproteinase (TIMPs). They were characterized in vitro and/or in vivo studies.
Looking for Partners:
To develop and commercialize the technology as a pharmaceutical composition with anti-angiogenic properties for treatment of cancer.
Stage of Development:
Discovery
Data Availability:
Mebendazole significantly increases the average survival rate by 63% in the syngeneic and xenograft orthotopic mouse glioma models. Effective in animal models for a dosage level 75% under that considered safe in humans.
Publications/Associated Cases:
PNAS September 16, 2008 vol. 105 no. 37 13775-13780
